KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Shares Issued (2016 - 2025)

Emergent BioSolutions' Shares Issued history spans 16 years, with the latest figure at -$800000.0 for Q3 2025.

  • For Q3 2025, Shares Issued fell 14.29% year-over-year to -$800000.0; the TTM value through Jun 2025 reached $100000.0, down 88.89%, while the annual FY2023 figure was $8.4 million, N/A changed from the prior year.
  • Shares Issued reached -$800000.0 in Q3 2025 per EBS's latest filing, down from $700000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $8.2 million in Q2 2023 to a low of -$12.5 million in Q4 2021.
  • Average Shares Issued over 5 years is $560000.0, with a median of $500000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: soared 228.0% in 2023, then plummeted 7.51619276799999e+16% in 2024.
  • A 5-year view of Shares Issued shows it stood at -$12.5 million in 2021, then surged by 76.0% to -$3.0 million in 2022, then surged by 106.67% to $200000.0 in 2023, then crashed by 450.0% to -$700000.0 in 2024, then dropped by 14.29% to -$800000.0 in 2025.
  • Per Business Quant, the three most recent readings for EBS's Shares Issued are -$800000.0 (Q3 2025), $700000.0 (Q2 2025), and $100000.0 (Q1 2025).